Hengrui Pharma(SH:600276) Xin Lang Cai Jing·2025-11-12 02:08Core Viewpoint - Heng Rui Medicine's stock price has shown a significant increase of 36.30% year-to-date, indicating strong market performance despite recent fluctuations [1][3]. Company Overview - Jiangsu Heng Rui Medicine Co., Ltd. is primarily engaged in the research, production, and sales of pharmaceuticals, focusing on oncology and related fields [2]. - The company's product portfolio includes anti-tumor drugs, analgesics, and contrast agents, with applications across various diseases including autoimmune, metabolic, cardiovascular, infectious, respiratory, hematological, pain management, neurological, ophthalmic, and renal diseases [2]. - The main revenue sources for the company are product sales (86.88%), licensing income (12.63%), and other income (0.49%) [2]. Financial Performance - As of September 30, 2025, Heng Rui Medicine reported a revenue of 23.188 billion yuan, representing a year-on-year growth of 14.85%, and a net profit attributable to shareholders of 5.751 billion yuan, up 24.50% year-on-year [3]. - The company has distributed a total of 9.303 billion yuan in dividends since its A-share listing, with 3.568 billion yuan distributed over the past three years [4]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 397,300, with an average of 16,058 circulating shares per person, a decrease of 8.21% from the previous period [3]. - Major shareholders include Hong Kong Central Clearing Limited and China Securities Finance Corporation, with notable changes in their holdings [4].